Pulse Biosciences
3957 Point Eden Way
Hayward
CA
94545
United States
Tel: 833-257-3393
Website: https://www.pulsebiosciences.com/
About Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company pursuing commercial introduction of our proprietary CellFX® System initially to the dermatology market. The CellFX System is powered by Nano-Pulse Stimulation™ (NPS™) technology, which delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular skin tissue. The unique cell-specific effects have the potential to significantly benefit patients across multiple medical applications. Designed as a multi-application platform, the initial commercial use of the CellFX System (upon regulatory approval) is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes.
Stock Symbol: PLSE
139 articles with Pulse Biosciences
-
Pulse Biosciences Reports First Quarter 2022 Financial Results
5/11/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2022.
-
Pulse Biosciences, Inc. Announces Commencement of Rights Offering - May 04, 2022
5/4/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that it has commenced its previously announced rights offering of up to $15,000,000 of units at the Initial Price.
-
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
4/28/2022
Pulse Biosciences, Inc. announced today it will report financial results for the first quarter of 2022 after market close on Wednesday, May 11, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT.
-
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference
4/26/2022
Pulse Biosciences, Inc today announced that one oral presentation and one poster presentation on the results of performing the CellFX procedure for lesion clearance will be delivered at the 2022 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting, taking place on April 27-30, 2022 in San Diego, California.
-
Pulse Biosciences, Inc. Announces Rights Offering - Apr 14, 2022
4/14/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.001 per share as of the close of market on April 25, 2022.
-
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results
3/31/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced financial results for the fourth quarter and full year of 2021.
-
Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022
3/21/2022
Pulse Biosciences, Inc. announced today it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 31, 2022.
-
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer
2/15/2022
Pulse Biosciences, Inc. today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer.
-
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission
2/8/2022
Pulse Biosciences, Inc. today announced an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System’s current labeling.
-
Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/1/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
-
Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results
1/11/2022
Pulse Biosciences, Inc. today announced preliminary unaudited fourth quarter 2021 financial and operational results.
-
Pulse Biosciences to Participate in the Stephens Annual Investment Conference
11/18/2021
Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced plans to participate in the Stephens Annual Investment Conference in Nashville, Tennessee.
-
Pulse Biosciences Reports Third Quarter 2021 Financial Results
11/15/2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter of 2021.
-
Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference
11/4/2021
Pulse Biosciences, Inc. today announced that members of management will present at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 1:40pm PT / 4:40pm ET.
-
Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021
11/2/2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2021 after market close on Monday, November 15, 2021.
-
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
10/5/2021
Pulse Biosciences, Inc. today announced the appointment of Laureen DeBuono to its Board of Directors.
-
Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference - Sep 02, 2021
9/2/2021
Pulse Biosciences, Inc., a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.
-
Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer
8/19/2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.
-
Pulse Biosciences Reports Second Quarter 2021 Financial Results
8/9/2021
Pulse Biosciences, Inc. today announced financial results for the second quarter of 2021.
-
Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021
7/26/2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021.